Dong-A gets Korean rights to Tobira's CVC in NASH cross-licensing agreement; deal ends
Executive Summary
Dong-A ST Co. Ltd. and Tobira Therapeutics Inc. entered concurrent licensing agreements to develop evogliptin/cenicriviroc (CVC) combinations to treat nonalcoholic steatohepatitis (NASH).
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Product or Technology Swap
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice